DSM inks antibody contract manufacturing deal for XD

- Last updated on GMT

Related tags: Contract manufacturing, Dsm biologics, Patent, Cell culture, Dsm

DSM inks antibody contract manufacturing deal for XD
DSM has signed an antibody contract manufacturing deal focused in its intensified cell culture process, XD.

Having entered into the agreement DSM will perform process development and manufacture of the antibodies using its XD cell culture technology that it claims can drive up to 15-fold increases in titre.

Karen King, president of DSM Biologics, said: “We are proud to announce that a major pharma company has chosen DSM's services and technology for three of their leading antibody pipeline projects for different indications​.”

The deal, the value of which DSM declined to reveal, comes as the firm tries to return its contract manufacturing business to growth. A difficult 2011 ended with fourth quarter earnings from the pharmaceutical business halving but since then DSM has shown small signs of improvement.

First quarter sales were up compared to a weak period one-year ago and the company has signed an active pharmaceutical ingredient (API) deal with Agenix and now a contract with the unnamed ‘major pharma company’.

The most recent deal makes use of the biologics capabilities that DSM management, speaking after fourth quarter results, tipped to help its contract manufacturing resurgence. Biologics assets were boosted in 2010 through a deal with the Australian Government and this site will serve the client.

We will apply our XD technology in combination with our technology portfolio, and manufacture from our Groningen, The Netherlands, and Brisbane, Australia facilities​,” King said. The Brisbane biologics facility spans 70,000 sq ft and is expected to begin operations next year.

Patent protection

DSM will use its XD process to increase output at its Brisbane plant. The technology, which uses a cell culture process to boost titre by up to 15 times, DSM claims, was recently protected by the granting of patents.

Reviews at patent offices across the globe recognized the patentability of DSM's XD process, amongst others the US and the Eurasian Patent Offices where patents have been granted. Other countries such as South Korea and Australia have provided allowance letters​,” King said.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us

Products

View more

Webinars